Background: Decoy receptor 3 (DcR3) has been reported to be overexpressed in a wide range of solid tumors, suggesting that DcR3 plays a crucial role in the development and progression of cancer. The present meta analysis assesses the association between DcR3 expression and prognosis in patients with solid tumors. Methods: Eligible studies were identified by searching the PubMed, Web of Science, Cochrane Library, EMBASE, Chinese CNKI, and Wan Fang databases. The pooled hazard ratios (HRs) for overall survival (OS) and recurrence free survival (RFS) were calculated using fixed effects models and random effects models, respectively. Results: Data from the 16 included studies, with 2209 patients, were reviewed and analyzed. DcR3 over expression was significantly associated with worse OS in patients with solid tumors, but its expression might not be related to RFS in malignancies. Conclusions: Current evidence demonstrates that increased DcR3 expression correlates with a poor prognosis in cancer patients, which suggests that the expression status of DcR3 is a useful biomarker for the prediction of prognosis in patients with solid tumors.